The H2 blocker famotidine has been added to the FDA's list of drug shortages, just over a week after a report said it was being tested in high intravenous doses as a potential treatment for COVID-19 patients, reported Bloomberg.
Drugmakers including Teva, Carlsbad Technology and Aurobindo reported increased demand for the tablets, which are known in branded form as Pepcid.
Teva said several bottles were on backorder with expected recovery in the fourth quarter, while Aurobindo said availability to support incremental demand is estimated for the week of June 15.
Meanwhile, Carlsbad reported to the FDA that "we do have some stock, however, due to such high demand, we cannot send to all customers. We send as much as we can."
The journal Science recently reported on a clinical trial in which critically ill COVID-19 patients at Northwell Health in the New York City area were receiving nine times the heartburn dose.
Interim results from 391 patients could be known in "a few weeks," according to a hospital researcher.
To read more NewsPoints articles, click here.